CompletedPhase 4

Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection

Iran400 participantsStarted 2007-03

Plain-language summary

Hemophilic patients are a known high risk groups for acquiring the hepatitis C. The surveillance data from Ministry Of Health in IR.Iran had shown that 60% of them are infected with HCV infection. We are trying the PEGASYS plus Ribavirin in Hemophilic patients with HCV.

Who can participate

Age range

12 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * HCV RNA positive * Age older than 12 years Exclusion Criteria: * Ongoing pregnancy or breast feeding * Hx of HCC * Hx of alcoholic liver disease * Hx of bleeding from esophageal varices * Hx of hemochromatosis * Hx of autoimmune hepatitis * Hx of Suicidal attempt * Hx of cerebrovascular dis * Hx of severe retinopathy * Hx of severe psoriasis * Hx of scleroderma * Hx of metabolic liver disease * Hx of SLE

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Early Virologic Response

Timeframe: After 12 weeks of Treatment

End of Treatment Response

Timeframe: 24 weeks for : Genotype 2 & 3; 48 Weeks for other genotype

Sustained Virologic Response

Timeframe: 24 weeks after Treatment

Rapid Virologic Response

Timeframe: One month after Treatment

Trial details

NCT IDNCT00707772

SponsorBaqiyatallah Medical Sciences University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-09

View on ClinicalTrials.gov More Hepatitis C trials

Who can participate

Age range

12 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.